Principal Financial Group Inc. Purchases Shares of 39,797 GRAIL, Inc. $GRAL

Principal Financial Group Inc. purchased a new stake in shares of GRAIL, Inc. (NASDAQ:GRAL) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 39,797 shares of the company’s stock, valued at approximately $2,057,000.

Several other hedge funds and other institutional investors have also made changes to their positions in GRAL. Farallon Capital Management LLC grew its stake in shares of GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after purchasing an additional 993,684 shares in the last quarter. Baker BROS. Advisors LP grew its position in GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after buying an additional 455,208 shares in the last quarter. Vanguard Group Inc. grew its position in GRAIL by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after buying an additional 163,790 shares in the last quarter. State Street Corp increased its stake in GRAIL by 38.8% during the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after buying an additional 510,546 shares during the period. Finally, Morgan Stanley raised its position in shares of GRAIL by 63.8% during the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after buying an additional 588,647 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on GRAL shares. Piper Sandler upped their price target on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Robert W. Baird set a $70.00 target price on GRAIL in a research report on Wednesday, May 6th. Finally, Wolfe Research started coverage on GRAIL in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, GRAIL presently has an average rating of “Hold” and an average target price of $67.78.

Insider Buying and Selling

In related news, insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.83% of the stock is currently owned by corporate insiders.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL will report its second-quarter 2026 financial results after the market closes on Aug. 5. The release gives investors a near-term catalyst to assess revenue growth, test adoption, cash usage and management’s outlook. GRAIL to Announce Second Quarter 2026 Financial Results
• Positive Sentiment: Management is scheduled to present at the Canaccord Genuity Growth Conference on Aug. 11. The event could provide additional commentary on commercial execution, the Galleri cancer-detection test and the company’s development strategy. GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
• Neutral Sentiment: Multiple investor-rights law firms reiterated that Aug. 4, 2026 is the deadline for investors to seek appointment as lead plaintiff in a federal securities class action. The notices are largely duplicative and do not represent new operating or financial developments for GRAIL. GRAIL Shareholder Action Reminder
• Negative Sentiment: The lawsuit alleges that GRAIL and certain executives made misleading statements or failed to disclose risks concerning the likelihood and timing of achieving the NHS-Galleri trial’s primary endpoint—a statistically significant reduction in Stage III-IV cancers. The litigation relates to investors who bought shares from May 13, 2025, through Feb. 19, 2026, and could create legal costs, reputational pressure and additional volatility. The allegations have not been proven. GRAIL Investor Alert

GRAIL Trading Up 12.1%

Shares of NASDAQ GRAL opened at $71.14 on Friday. GRAIL, Inc. has a twelve month low of $29.95 and a twelve month high of $118.84. The firm has a 50-day moving average of $66.75 and a two-hundred day moving average of $67.59. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -6.86 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The company had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $39.16 million. As a group, research analysts predict that GRAIL, Inc. will post -10.91 earnings per share for the current year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.